Merck starts study of inflammatory antibody; Investigators find new preclinical candidates for Parkinson's, cancer;

 @FierceBiotech: ICYMI: 10 startups fueling pharma in social media. Special report | Follow @FierceBiotech

 @JohnCFierce: Under review and well past Ph3: Can Novartis gain anything from its latest breakthrough drug win at the FDA? Article | Follow @JohnCFierce

 @RyanMFierce: The news: Ablynx heads to PhI w/ German Merck. The takeaway: Misspell Merck Serono, and it rhymes with 'My Sharona." Story | Follow @RyanMFierce

 @EmilyMFierce: New at FierceBiotechResearch.com: Penn scientists create human-cell model of pancreatic cancer. Story | Follow @EmilyMFierce

> Merck Serono dosed the first person in a Phase I clinical trial of ALX-0761 for inflammatory diseases, which is partnered with Ablynx. Release

> Scripps researchers say they've found a pair of inhibitors in one molecule that could be useful in fighting Parkinson's disease. Release

> Investigators at the University of Rochester say they've found a chemical that makes naked mole rats immune to cancer, and say it could have applications to humans as well. Story

> Sanofi's ($SNY) cancer drug Zaltrap has fallen into another price trap. The cost watchdog in the U.K. said it does not find the benefits of the colorectal cancer drug outweigh its high price. Story

Medical Device News

 @FierceMedDev: Endo's AMS owes $54.5M in vaginal mesh lawsuit. News | Follow @FierceMedDev

 @DamianFierce: Philips' is enduring its third ventilator recall in about a year, drawing a deadly FDA warning. Report | Follow @DamianFierce

 @MichaelGFierce: Biosensor nanoparticles deliver cancer drug with precise, 3-D imaging. FierceDrugDelivery story | Follow @MichaelGFierce

> GE pads mammography prowess with Korean buyout. Story

> Abbott wins FDA nod for hep C gene test. Article

> France ponies up for study of GI Dynamics' obesity tech. More

> Medtronic ups dividend, eyes share buyback. Item

Pharma News

 @FiercePharma: Needy Forest Labs reportedly eyes a bid for Elan. But why? Yesterday's story | Follow @FiercePharma

 @EricPFierce: Who manufactures the top selling diabetes treatments? Novo has 5 of top 10, but not the top two. Special report | Follow @EricPFierce

> Pfizer's Viagra patent in Europe expires today. Article

> Teva's one-pill 'morning after' drug allowed OTC. Story

> Bristol-Myers Squibb gets a boost for leukemia drug Sprycel. Report

And Finally… A new study that finds men who are infertile because they don't produce sperm may suffer from a higher risk of cancer. Report

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.